licochalcone d

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

licochalcone D: isolated from Glycyrrhiza inflata; inhibits phosphorylation of NF-kappaB p65 in LPS signaling pathway [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Glycyrrhiza	genus	A genus of leguminous herbs or shrubs whose roots yield GLYCYRRHETINIC ACID and its derivative, CARBENOXOLONE.[MeSH]	Fabaceae	The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID Source	ID
PubMed CID	10473311
CHEMBL ID	1644932
MeSH ID	M0536803

Synonyms (23)

Synonym
LMPK12120425
licochalcone d
CHEMBL1644932
licochalcone d [mi]
(2e)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-(4-hydroxy-3-(3-methyl-2-butenyl)phenyl)-2-propen-1-one
2-propen-1-one, 3-(3,4-dihydroxy-2-methoxyphenyl)-1-(4-hydroxy-3-(3-methyl-2-butenyl)phenyl)-, (e)-
144506-15-0
unii-3p0sh94v09
3p0sh94v09 ,
2-propen-1-one, 3-(3,4-dihydroxy-2-methoxyphenyl)-1-(4-hydroxy-3-(3-methyl-2-butenyl)phenyl)-, (2e)-
S6899
DTXSID00162738
bdbm50483309
AKOS037515337
HY-N4187
CS-0032380
Q27257833
(e)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]prop-2-en-1-one
(e)-3-(3,4-dihydroxy-2-methoxyphenyl)-1-(4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl)prop-2-en-1-one
MS-25526
2-propen-1-one, 3-(3,4-dihydroxy-2-methoxyphenyl)-1-[4-hydroxy-3-(3-methyl-2-butenyl)p henyl]-, (e)-
XL173147
E88806

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay ID	Title	Year	Journal	Article
AID1061196	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 2 uM after 24 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID1061200	Antiinflammatory activity in RBL2H3 cells assessed as inhibition of degranulation	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID549515	Inhibition of Influenza A H1N1 virus neuraminidase activity after 2 hrs by spectrofluorometry	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID549518	Inhibition of Influenza A H9N2 virus neuraminidase activity after 2 hrs by spectrofluorometry	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1463921	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells at 2.5 to 20 uM incubated for 6 hrs by ARE-driven luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID549519	Noncompetitive inhibition of Influenza A H1N1 virus neuraminidase activity by Lineweaver-Burk plot analysis	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1061199	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production at 2 uM after 18 hrs by Griess assay relative to control	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID1463920	Activation of Nrf2 (unknown origin) expressed in human HepG2 cells at 10 uM incubated for 6 hrs by ARE-driven luciferase reporter gene assay relative to untreated control	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID1061198	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production at 20 uM after 18 hrs by Griess assay relative to control	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID1463923	Cytotoxicity in human HepG2 cells expressing Nrf2/ARE-driven luciferase at 20 to 40 uM incubated for 6 hrs	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Nrf2 activators from Glycyrrhiza inflata and their hepatoprotective activities against CCl
AID549521	Inhibition of Clostridium perfringens neuraminidase	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Chalcones as novel influenza A (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata.
AID1061197	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production after 18 hrs by Griess assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis of licochalcone analogues with increased anti-inflammatory activity.
AID1061195	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 20 uM after 24 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Synthesis of licochalcone analogues with increased anti-inflammatory activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (9.09)	29.6817
2010's	7 (63.64)	24.3611
2020's	3 (27.27)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	19.27 (24.57)
Research Supply Index	2.48 (2.92)
Research Growth Index	5.56 (4.65)
Search Engine Demand Index	18.60 (26.88)
Search Engine Supply Index	3.00 (0.95)

This Compound (19.27)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
1-anilino-8-naphthalenesulfonate 1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.	2.31	1	aminonaphthalene; naphthalenesulfonic acid	fluorescent probe
galactose galactopyranose : The pyranose form of galactose.	2.31	1	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
malondialdehyde Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.	2.11	1	dialdehyde	biomarker
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	2.06	1	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
indicine indicine: RN given refers to (1R-(1alpha,7(2R,3S),7abeta))-isomer	2.05	1	carboxylic ester; pyrrolizines
liquiritigenin liquiritigenin: structure given in first source; isolated from Pterocarpus marsupium. 4',7-dihydroxyflavanone : A dihydroxyflavanone in which the two hydroxy substituents are located at positions 4' and 7.. liquiritigenin : A dihydroxyflavanone compound having the two hydroxy substituents at the 4'- and 7-positions. Isolated from the root of Glycyrrhizae uralensis, it is a selective agonist for oestrogen receptor beta.	2.15	1	4',7-dihydroxyflavanone	hormone agonist; plant metabolite
gefitinib [no description available]	7.25	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
glabridin [no description available]	2.15	1	hydroxyisoflavans	antiplasmodial drug
6,8-diprenylgenistein 6,8-diprenylgenistein: a lysoPAF acetyltransferase inhibitor isolated from licorice root; structure in first source. 5,7,4'-trihydroxy-6,8-diprenylisoflavone : A member of the class of 7-hydroxyisoflavones that is genistein substituted by prenyl groups at positions 6 and 8. It has been isolated from Derris scandens and Glycyrrhiza uralensis.	2.15	1	7-hydroxyisoflavones	antibacterial agent; plant metabolite
Euchrestaflavanone A [no description available]	2.15	1	flavanones
isoliquiritigenin [no description available]	2.79	3	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist
formononetin [no description available]	2.15	1	4'-methoxyisoflavones; 7-hydroxyisoflavones	phytoestrogen; plant metabolite
2'-hydroxyformononetin 2'-hydroxyformononetin : A member of the class of 4'-methoxyisoflavones that is formononetin with a hydroxy group at the 2'position.	2.15	1	4'-methoxyisoflavones; 7-hydroxyisoflavones	anti-inflammatory agent
genistein [no description available]	2.15	1	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
isobavachalcone isobavachalcone: RN given for (E)-isomer; structure in first source. isobavachalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'.	2.15	1	chalcones; polyphenol	antibacterial agent; metabolite; platelet aggregation inhibitor
licoisoflavone a licoisoflavone A: from Sophra mooracroftiana; structure in first source. licoisoflavone A : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone substituted by additional hydroxy groups at positions 5, 2' and 4' and a prenyl group at position 3'.	2.15	1	7-hydroxyisoflavones	metabolite
wighteone wighteone : A member of the class of 7-hydroxyisoflavones that is isoflavone substituted by hydroxy groups at positions 5, 7 and 4' and a prenyl group at position 6. It has been isolated from Ficus mucuso.	2.15	1	7-hydroxyisoflavones	antifungal agent; plant metabolite
4',7-dihydroxyflavone 4',7-dihydroxyflavone: inducer of nod gene. 4',7-dihydroxyflavone : A dihydroxyflavone in which the two hydroxy substituents are located at positions 4' and 7.	2.15	1	dihydroxyflavone	metabolite
eurycarpin b eurycarpin B: from the roots of Glycyrrhiza eurycarpa; structure in first source	2.15	1	isoflavonoid
licochalcone a licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer	8.2	5	chalcones
licochalcone b licochalcone B: isolated from Glycyrrhiza inflata; inhibits phosphorylation of NF-kappaB p65 in LPS signaling pathway; structure in first source	8.02	4	chalcones
Licoflavone A [no description available]	2.15	1	flavones
7,4'-dihydroxy-3'-methoxyisoflavone 7,4'-dihydroxy-3'-methoxyisoflavone : A member of the class of 7-hydroxyisoflavones that is 7,4'-dihydroxyisoflavone substituted by a methoxy group at position 3'. It is isolated from the heart woods of Maackia amurensis subsp buergeri and Dalbergia louveli and exhibits antiplasmodial ativity.	2.15	1	7-hydroxyisoflavones; methoxyisoflavone	antiplasmodial drug; metabolite
licoisoflavone b licoisoflavone B: from Sophra mooracroftiana; structure in first source	2.15	1
semilicoisoflavone b semilicoisoflavone B: isolated from Glycyrrhiza uralensis; structure in first source. semilicoisoflavone B : A member of the class of 7-hydroxyisoflavones that is 2',2'-dimethyl-2'H,4H-3,6'-bichromen-4-one substituted by hydroxy groups at positions 5, 7 and 8'. It has been isolated from Glycyrrhiza uralensis.	2.15	1	7-hydroxyisoflavones	EC 1.1.1.21 (aldehyde reductase) inhibitor; plant metabolite
alpinumisoflavone alpinumisoflavone: extract from twigs of poisonous British plant	2.15	1	isoflavanones	metabolite
licochalcone c licochalcone C: has cardioprotective, antioxidant, anti-inflammatory and anti-apoptotic activities; isolated from licorice; structure in first source	2.83	3
licoflavone c licoflavone C: Antimutagenic Agent; a naturally occurring prenyl-flavone extracted from Genista ephedroides; structure in first source	2.15	1
Kanzonol B [no description available]	2.15	1	chalcones
2',3,4,4'-tetrahydroxy-5-prenylchalcone [no description available]	2.06	1
Licoflavone B licoflavone B: Schistosomicide from Glycyrrhiza inflata; structure in first source	2.15	1	flavones
11-deoxy glycyrrhetinic acid [no description available]	2.15	1	triterpenoid
licochalcone e licochalcone E: from roots of Glycyrrhiza inflata; structure in first source	2.61	2

Condition	Relationship Strength	Studies
Acute Liver Injury, Drug-Induced [description not available]	2.15	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.15	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.15	1
Carcinoma, Non-Small Cell Lung [description not available]	2.25	1
Cancer of Lung [description not available]	2.25	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.25	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.25	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.31	1
Malignant Melanoma [description not available]	2.17	1
Invasiveness, Neoplasm [description not available]	2.17	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	7.17	1
Carcinoma, Squamous Cell of Head and Neck [description not available]	2.21	1
Cancer of Mouth [description not available]	2.21	1
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	2.21	1
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.21	1
Innate Inflammatory Response [description not available]	2.11	1
Injury, Myocardial Reperfusion [description not available]	2.11	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.11	1

chemdatabank.com